Galectin-1 and Galectin-3 in B-Cell Precursor Acute Lymphoblastic Leukemia

Fei Fei1, Mingfeng Zhang2, Somayeh S Tarighat1

  • 1Section of Molecular Carcinogenesis, Department of Pediatrics, Division of Hematology/Oncology and Bone Marrow Transplantation, The Saban Research Institute of Children's Hospital, Los Angeles, CA 90027, USA.

Summary

Blocking Galectin-1 and Galectin-3 in bone marrow stromal cells can reduce chemotherapy resistance in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Targeting these galectins enhances drug sensitivity and may improve BCP-ALL treatment outcomes.